Navigation Links
Senomyx Announces Fourth Quarter And Full Year 2012 Financial Results And Initiation Of New Direct Sales Strategy
Date:3/15/2013

oducts.  Firmenich has exclusive rights to commercialize S9632 for food applications and shares co-exclusive rights with Senomyx for powdered beverages.  Firmenich has started demonstrating the capabilities of S9632 to manufacturers for use within their licensed fields.  Senomyx intends to implement the direct sales strategy to sell S9632 to flavor companies for end-use in non-alcoholic beverages and powdered beverages. 

S2383 can be used to restore the desired taste profile of products in which sucralose, a commonly used high-intensity sweetener, has been reduced.  Firmenich is currently commercializing S2383 for use in all food and beverage product categories.  Products that contain S2383 are being marketed in North America and Latin America.  Follow-on launches are being planned by manufacturers that currently use S2383 in their products, and additional product development work for potential usage of S2383 in a variety of products is underway.Savory Taste Program:
Senomyx's Savory Flavors are intended to reduce or replace added monosodium glutamate (MSG) in foods.  Each of the Savory Flavors provides a distinct new savory taste sensation.  The Savory Flavors are very versatile and can be combined with other ingredients to create unique new flavor blends.  They can be used in a variety of food products including sauces, frozen foods, cooking aids, soups, and snack foods. 

Sales and product launches of new and reformulated established products that contain a Senomyx Savory Flavor are being conducted by two Senomyx partners, both of which are global food companies.  The marketed products have been launched into the retail, industrial, and food service channels in selected countries within Africa, Asia, Latin America, and the Middle East, with additional product launches expected during this year.  Four of the Savory Flavors will be considered legal for use in European Union countries
'/>"/>

SOURCE Senomyx
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Senomyx To Webcast Corporate Presentation At The 25th Annual ROTH Conference
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... - Elsevier, a world-leading provider of scientific, technical and ... of a recent study in Reproductive BioMedicine ... that those with an abnormal chromosomal composition can be ... to blastocysts, thereby classifying the risk of genetic abnormality ... group has undertaken a retrospective study, using their predictive ...
(Date:5/17/2013)... May 17, 2013 New ... most innovative thought leaders of the medical device ... East conference and expo, from June 18-20 in ... (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) , ... deliver industry professionals practical presentations and implementable solutions ...
(Date:5/17/2013)... Calif. , May 17, 2013 /PRNewswire-iReach/ -- ... has been reached with Switzerland ... of anti-infective human monoclonal antibody (mAb) products, and ... human mAb products for treatment of infections by ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
(Date:5/17/2013)... The paradigm of ‘one drug, one ... can help predict the adverse and therapeutic effects of ... of Computational Biology at the Genomics Laboratory, Covance, will ... high-quality genomics when used as part of the QC ... data sets to identify key clinical targets even in ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... , TORONTO , Jan. 28 ... company developing innovative immune-based biologics, today announced that Dr. ... Directors as an independent director. Trillium Chairman Dr. ... to welcome such an experienced biotech executive as Dr. ...
... ... DNA (or RNA). To help illustrate the basics of DNA origami, Harvard’s Wyss Institute has ... simple, abstract representation of a DNA molecule and then allowing it to self assemble. ... Boston, Mass. (PRWEB) January 28, ...
... , PRINCETON, N.J. , Jan. 27 Covance Inc. ... ended December 31, 2009 of $0.64 per diluted ... a GAAP basis, inclusive of $0.10 per share in gains ... tax resolutions in the third quarter.  Excluding the gains on sales and ...
Cached Biology Technology:Trillium adds industry veteran Dr. Mike Gresser to its Board of Directors 2Trillium adds industry veteran Dr. Mike Gresser to its Board of Directors 3Wyss Institute Launches "Molecular Origami" Interactive Feature 2Wyss Institute Launches "Molecular Origami" Interactive Feature 3Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 2Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 3Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 4Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 5Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 6Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 7Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 8Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 9Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 10Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 11Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 12Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 13Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 14Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 15Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 16Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share 17
(Date:5/17/2013)... interaction of a group of proteins in the brain ... a new target that could increase cell survival. , ... of Biochemistry and published in the EMBO journal ... lead to new therapies for stroke and other brain ... the team which identified a protein, known as SUMO, ...
(Date:5/17/2013)... Federation of American Societies for Experimental Biology (FASEB) released ... Health (NIH) funding trends highlighting the devastating impact of ... The FASEB analysis follows a May 15th Senate Appropriations ... who testified that the $1.6 billion cut the agency ... a substantial impact on the scientific community." , ...
(Date:5/16/2013)... (Maximizing Access to Research Careers) Program has announced ... Developmental Biology (SDB) 72nd Annual Meeting in Cancun, ... meant to promote the entry of students, postdoctorates ... of the basic science community and to encourage ... 2013 Annual Meeting. , Awards are given to ...
Breaking Biology News(10 mins):SUMO wrestling cells reveal new protective mechanism target for stroke 2
... Reportlinker.com announces that a new ... Biometrics: Technologies and Global Markets ... AND OBJECTIVESThis report studies the global as well as ... purpose of locating newer markets and expanding the present ...
... project using cameras mounted on unmanned aircraft flying over the ... declining sea ice and using the same aerial photos to ... The project is the first to use aircraft to monitor ... observers at risk, said Elizabeth Weatherhead of the University of ...
... reactions that asthmatics suffer towards a common mould have ... mould growing in their own lungs. The research ... has been published in the December 2010 issue of ... Medicine . The team based in the Institute ...
Cached Biology News:Reportlinker Adds Biometrics: Technologies and Global Markets 2Reportlinker Adds Biometrics: Technologies and Global Markets 3Reportlinker Adds Biometrics: Technologies and Global Markets 4Reportlinker Adds Biometrics: Technologies and Global Markets 5Reportlinker Adds Biometrics: Technologies and Global Markets 6Reportlinker Adds Biometrics: Technologies and Global Markets 7Reportlinker Adds Biometrics: Technologies and Global Markets 8Reportlinker Adds Biometrics: Technologies and Global Markets 9Reportlinker Adds Biometrics: Technologies and Global Markets 10Reportlinker Adds Biometrics: Technologies and Global Markets 11Reportlinker Adds Biometrics: Technologies and Global Markets 12Reportlinker Adds Biometrics: Technologies and Global Markets 13Reportlinker Adds Biometrics: Technologies and Global Markets 14Reportlinker Adds Biometrics: Technologies and Global Markets 15Reportlinker Adds Biometrics: Technologies and Global Markets 16Reportlinker Adds Biometrics: Technologies and Global Markets 17Reportlinker Adds Biometrics: Technologies and Global Markets 18Reportlinker Adds Biometrics: Technologies and Global Markets 19Reportlinker Adds Biometrics: Technologies and Global Markets 20Reportlinker Adds Biometrics: Technologies and Global Markets 21Reportlinker Adds Biometrics: Technologies and Global Markets 22High-tech software, umanned planes allow scientists to keep tabs on Arctic seals 2High-tech software, umanned planes allow scientists to keep tabs on Arctic seals 3New asthma research breaks the mold 2
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
Medium for cryopreserving subcutaneous or omental preadipocytes...
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin: ...
... ultra high yield technology is fast - ... aRNA for gene array analysis ... , Kits specific for templates with ... , All kits contain SUPERaseIn ...
Biology Products: